[go: up one dir, main page]

CY1118232T1 - Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων - Google Patents

Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων

Info

Publication number
CY1118232T1
CY1118232T1 CY20161101170T CY161101170T CY1118232T1 CY 1118232 T1 CY1118232 T1 CY 1118232T1 CY 20161101170 T CY20161101170 T CY 20161101170T CY 161101170 T CY161101170 T CY 161101170T CY 1118232 T1 CY1118232 T1 CY 1118232T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical properties
compounds
administering
therapeutic methods
pharmaceutical
Prior art date
Application number
CY20161101170T
Other languages
English (en)
Inventor
Manoj C Desai
Allen Y Hong
Hon C Hui
Hongtao Liu
Radall W Vivian
Lianhong Xu
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39522375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118232(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of CY1118232T1 publication Critical patent/CY1118232T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μία ένωση Τύπου IV, ή ένα φαρμακευτικώς αποδεκτό άλας, διαλύτωμα, και/ή εστέρα αυτής, συνθέσεις που περιέχουν αυτές τις ενώσεις, θεραπευτικές μεθόδους που περιλαμβάνουν τη χορήγηση αυτών των ενώσεων και θεραπευτικές μεθόδους που περιλαμβάνουν τη χορήγηση αυτών των ενώσεων με τουλάχιστον έναν επιπρόσθετο θεραπευτικό παράγοντα.
CY20161101170T 2007-02-23 2016-11-15 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων CY1118232T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90322807P 2007-02-23 2007-02-23
US95871607P 2007-07-06 2007-07-06
EP08743531.9A EP2118082B1 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics

Publications (1)

Publication Number Publication Date
CY1118232T1 true CY1118232T1 (el) 2017-06-28

Family

ID=39522375

Family Applications (9)

Application Number Title Priority Date Filing Date
CY20161101075T CY1118292T1 (el) 2007-02-23 2016-10-25 Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
CY20161101152T CY1118219T1 (el) 2007-02-23 2016-11-09 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY20161101168T CY1118227T1 (el) 2007-02-23 2016-11-14 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY20161101170T CY1118232T1 (el) 2007-02-23 2016-11-15 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY2017003C CY2017003I2 (el) 2007-02-23 2017-01-04 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY2017001C CY2017001PI1 (el) 2007-02-23 2017-01-04 Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
CY2017002C CY2017002I2 (el) 2007-02-23 2017-01-04 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY20201100220T CY1122761T1 (el) 2007-02-23 2020-03-13 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY2020011C CY2020011I1 (el) 2007-02-23 2020-06-05 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CY20161101075T CY1118292T1 (el) 2007-02-23 2016-10-25 Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
CY20161101152T CY1118219T1 (el) 2007-02-23 2016-11-09 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY20161101168T CY1118227T1 (el) 2007-02-23 2016-11-14 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων

Family Applications After (5)

Application Number Title Priority Date Filing Date
CY2017003C CY2017003I2 (el) 2007-02-23 2017-01-04 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY2017001C CY2017001PI1 (el) 2007-02-23 2017-01-04 Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
CY2017002C CY2017002I2 (el) 2007-02-23 2017-01-04 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY20201100220T CY1122761T1 (el) 2007-02-23 2020-03-13 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY2020011C CY2020011I1 (el) 2007-02-23 2020-06-05 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων

Country Status (32)

Country Link
US (7) US9891239B2 (el)
EP (5) EP4403221A3 (el)
JP (9) JP4881446B2 (el)
KR (2) KR101664154B1 (el)
CN (2) CN101679325B (el)
AP (2) AP3915A (el)
AR (1) AR065439A1 (el)
AU (1) AU2008218186C1 (el)
BR (1) BRPI0807581A2 (el)
CA (1) CA2678907C (el)
CY (9) CY1118292T1 (el)
DK (2) DK3150586T3 (el)
EA (1) EA019893B1 (el)
ES (6) ES2603617T3 (el)
FI (1) FI2487161T4 (el)
FR (4) FR17C1000I2 (el)
HK (1) HK1137451A1 (el)
HR (5) HRP20161476T4 (el)
HU (6) HUE031707T2 (el)
IL (1) IL200550A0 (el)
LT (9) LT2487162T (el)
LU (1) LUC00156I2 (el)
MX (1) MX2009008935A (el)
NO (4) NO2017002I2 (el)
NZ (1) NZ579802A (el)
PL (3) PL3150586T3 (el)
PT (6) PT3150586T (el)
SG (2) SG10201705929QA (el)
SI (1) SI3150586T1 (el)
TW (1) TWI533868B (el)
WO (1) WO2008103949A1 (el)
ZA (1) ZA200905882B (el)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
PT1778251E (pt) 2004-07-27 2011-06-29 Gilead Sciences Inc Análogos de fosfonato de compostos inibidores de vih
EA020489B1 (ru) * 2006-07-07 2014-11-28 Джилид Сайэнс, Инк. Модуляторы фармакокинетических свойств лекарственных средств
WO2008027932A2 (en) * 2006-08-31 2008-03-06 Abbott Laboratories Cytochrome p450 oxidase inhibitors and uses thereof
SI2487161T2 (sl) 2007-02-23 2024-07-31 Gilead Sciences, Inc. Modulatorji farmakokinetičnih lastnosti terapevtikov
CN101679325B (zh) * 2007-02-23 2013-08-28 吉里德科学公司 治疗剂的药代动力学特性调节剂
EP2222324A2 (en) * 2007-11-20 2010-09-01 Concert Pharmaceuticals, Inc. Boceprevir derivatives for the treatment of hcv infections
CA2710679A1 (en) * 2008-01-04 2009-07-16 Gilead Sciences, Inc. Inhibitors of cytochrome p450
CN103479584A (zh) * 2008-05-02 2014-01-01 吉里德科学公司 固体载体颗粒在改善药物制剂加工性中的应用
CN102089318B (zh) 2008-07-08 2014-05-21 吉里德科学公司 Hiv抑制剂化合物的盐
AP2011005745A0 (en) 2008-12-09 2011-06-30 Gilead Sciences Inc Modulators of toll-like receptors.
AU2015200637C1 (en) * 2009-02-06 2017-08-03 Gilead Sciences, Inc. Tablets for combination therapy
CN102307573B (zh) 2009-02-06 2013-09-11 吉里德科学公司 用于联合治疗的片剂
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
WO2010151672A2 (en) * 2009-06-26 2010-12-29 Georgetown University Amino acid derived ureas
PL2932970T3 (pl) 2010-01-27 2018-08-31 Viiv Healthcare Co Terapia antywirusowa
NL2005306C2 (nl) * 2010-09-02 2012-03-05 Tersia Nederland B V Koppelstuk voor meerlaagse leidingen, lasapparaaat voor het verbinden van het koppelstuk met meerlaagse leidingen, werkwijze van koppelen en een samenstel verkregen via de werkwijze.
WO2012045007A1 (en) 2010-10-01 2012-04-05 Gilead Sciences, Inc. Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester
EP2640362B2 (en) * 2010-11-19 2021-12-01 Gilead Sciences, Inc. Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate
WO2012088156A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
WO2012088153A1 (en) * 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
US20130274254A1 (en) 2010-12-21 2013-10-17 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
EP2472320A2 (en) 2010-12-30 2012-07-04 Rohm and Haas Electronic Materials LLC Compositions comprising base-reactive component and processes for photolithography
PT2705027E (pt) * 2011-05-02 2015-09-11 Gilead Sciences Inc Sais sólido de amorfo de cobicistat (gs-9350)
US20140142070A1 (en) 2011-07-07 2014-05-22 Janssen R&D Ireland Darunavir combination formulations
PE20141328A1 (es) 2011-08-16 2014-10-04 Gilead Sciences Inc Tenofovir alafenamida hemifumarato
RU2014129937A (ru) 2012-02-03 2016-03-27 Джилид Сайэнс, Инк. Способы и промежуточные соединения для получения фармацевтических агентов
WO2013115916A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
WO2013116730A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
WO2014057498A2 (en) 2012-10-08 2014-04-17 Mylan Laboratories Ltd. Process for the preparation of cobicistat intermediates
EP2911674A1 (en) * 2012-10-23 2015-09-02 Cipla Limited Pharmaceutical antiretroviral composition
DK3608325T3 (da) 2012-12-21 2022-08-22 Gilead Sciences Inc Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
JP2016504364A (ja) 2012-12-26 2016-02-12 アッシア・ケミカル・インダストリーズ・リミテッド コビシスタット塩
EP3019503B1 (en) 2013-07-12 2017-09-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (el) 2013-07-12 2018-07-21
JP6574415B2 (ja) 2013-10-07 2019-09-11 ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランド・アンリミテッド・カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ Ｕｎｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ アタザナビルおよびコビシスタットのｈｉｖ治療製剤
US9975864B2 (en) 2013-12-03 2018-05-22 Mylan Laboratories Limited Preparation of cobicistat intermediates
WO2015145324A1 (en) 2014-03-25 2015-10-01 Mylan Laboratories Ltd Process for the preparation of cobicistat
NO2717902T3 (el) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
CN114588157A (zh) * 2014-07-17 2022-06-07 Chdi基金会股份有限公司 用于治疗hiv相关病症的方法和组合物
PT3194401T (pt) 2014-09-16 2020-12-23 Gilead Sciences Inc Formas sólidas de modulador de recetor tipo toll
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
WO2016161382A1 (en) 2015-04-02 2016-10-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN105198829B (zh) * 2015-08-15 2017-10-31 浙江永宁药业股份有限公司 一种可比司他中间体的制备方法及其中间体和用途
CN107513046B (zh) * 2016-06-15 2019-12-13 江苏欧信制药有限公司 一种可比司他的合成方法
US20180036289A1 (en) * 2016-08-04 2018-02-08 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
US20190175511A1 (en) 2016-08-08 2019-06-13 Hetero Labs Limited A Multi-Class Anti-Retroviral Composition
KR101908853B1 (ko) * 2017-05-17 2018-10-16 경북대학교 산학협력단 아세틸시코닌을 유효성분으로 함유하는 시토크롬 p450 동효소 억제용 조성물
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
AU2018378832B9 (en) 2017-12-07 2021-05-27 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN109912530A (zh) * 2017-12-13 2019-06-21 上海奥博生物医药技术有限公司 一种可比司他原料杂质的制备方法
CA3089388A1 (en) * 2018-01-30 2019-08-08 Sun Biopharma, Inc. Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127689A (en) * 1872-06-11 Improvement in differential pulley-blocks
US108617A (en) * 1870-10-25 Improvement in ore-pulverizers
US77295A (en) * 1868-04-28 theqdoee krausch
US143314A (en) * 1873-09-30 Improvement in condenser-tube fastenings
US115665A (en) * 1871-06-06 Improvement in folding-steps for carriages
US181902A (en) * 1876-09-05 Improvement in bell toys
US191319A (en) * 1877-05-29 Improvement in stoves
US199851A (en) * 1878-01-29 Improvement in circular saws
US99902A (en) * 1870-02-15 1870-02-15 Improvement in adjustable dials for travelers watches
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3882114A (en) 1967-10-26 1975-05-06 Oreal N-(morpholinomethyl carbamyl) cysteamine and glycine
GB1241024A (en) 1968-10-29 1971-07-28 Boehringer Sohn Ingelheim Pharmaceutical tablet base and a process for its manufacture
NL149711B (nl) 1970-06-15 1976-06-15 Sumitomo Chemical Co Werkwijze voor het vervaardigen van pillen, alsmede de aldus vervaardigde pillen.
GB1339764A (en) 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
CH586568A5 (el) 1972-04-10 1977-04-15 Hoffmann La Roche
US3957774A (en) 1972-04-17 1976-05-18 L'oreal N-morpholinomethyl-n-'-substituted ethyl and propylureas
DE2845326C2 (de) 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US5142056A (en) 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
HU186777B (en) 1981-07-09 1985-09-30 Magyar Tudomanyos Akademia Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them
US4603143A (en) 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
GB8413191D0 (en) 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
FR2631620B1 (fr) 1988-05-19 1990-07-27 Rhone Poulenc Chimie Nouvelle silice precipitee absorbante et composition a base de cette s ilice
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5362912A (en) * 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
EP0428849A3 (en) 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
IE20010533A1 (en) 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
JPH06127981A (ja) 1992-03-03 1994-05-10 Fuainiteii Kk 複合複層ガラス及びそれを使用した窓
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
WO1994014436A1 (en) 1992-12-29 1994-07-07 Abbott Laboratories Retroviral protease inhibiting compounds
WO1995005808A1 (en) 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5763464A (en) * 1995-11-22 1998-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same
JP4064476B2 (ja) 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド 二酸化珪素を有する球状凝集した澱粉
US6348216B1 (en) 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6361794B1 (en) 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4494539B2 (ja) 1997-02-28 2010-06-30 ディーエスエム アイピー アセッツ ビー．ブイ． 流動自由な乾燥粒子
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
FR2767071B1 (fr) 1997-08-06 1999-09-10 Rhodia Chimie Sa Composition comprenant un liquide absorbe sur un support a base de silice precipitee
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
FR2773994B1 (fr) 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
JP4027535B2 (ja) 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
HU229501B1 (hu) 1999-06-04 2014-01-28 Abbvie Inc HIV proteáz gátló vegyületet tartalmazó gyógyszerkészítmények
CA2386850C (en) 1999-10-06 2010-03-30 Piet Tom Bert Paul Wigerinck Hexahydrofuro[2,3-b]furan-3-yl-n-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US6448245B1 (en) * 2000-05-04 2002-09-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
US20030035834A1 (en) 2000-05-26 2003-02-20 Pawan Seth Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
TWI290053B (en) 2000-09-19 2007-11-21 Daiichi Seiyaku Co Medicinal composition for preventing the generation of a disagreeable taste
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6524615B2 (en) 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
DE10112651A1 (de) 2001-03-16 2002-09-19 Degussa Inhomogene Kieselsäuren als Trägermaterial
KR100568380B1 (ko) 2001-05-01 2006-04-05 화이자 프로덕츠 인코포레이티드 저 투약량 약학 조성물의 제조 방법
DE10126163A1 (de) 2001-05-30 2002-12-05 Degussa Pharmazeutische Zubereitungen
CN100579514C (zh) 2001-07-06 2010-01-13 生命周期药物公司 通过受控制的凝聚而制备颗粒物的方法以及提高生物利用度的方法
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US7815936B2 (en) 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
AU2002219964A1 (en) 2001-11-29 2003-06-17 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US7285566B2 (en) * 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
CA2472372C (en) * 2002-01-17 2010-08-17 Melissa Egbertson Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
US6926906B2 (en) 2002-02-20 2005-08-09 M./S. Strides, Inc. Orally administrable pharmaceutical formulation
US6726448B2 (en) 2002-05-15 2004-04-27 General Electric Company Ceramic turbine shroud
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
DE10250711A1 (de) 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
TR200401663T1 (tr) * 2002-11-20 2005-04-21 Japan Tobacco Inc. 4-oksokuinolin bileşiği ve bunun HIV integraz inhibitörü olarak kullanımı.
US7189416B2 (en) 2002-11-23 2007-03-13 Glykon Technologies Group, Llc Method for stable and controlled delivery of (-)-hydroxycitric acid
JP2004184681A (ja) 2002-12-03 2004-07-02 Konica Minolta Holdings Inc 熱現像感光材料
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
US20060115524A1 (en) 2003-02-19 2006-06-01 H. Lundbeck A/S Method for preparation of an agglomerate using melt agglomeration
FR2851918B1 (fr) 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
JP4018664B2 (ja) 2003-04-30 2007-12-05 第一三共株式会社 安定化固形製剤
DE10337198A1 (de) 2003-08-13 2005-03-17 Degussa Ag Träger auf Basis von Granulaten, die aus pyrogen hergestelltem Siliciumdioxiden hergestellt sind
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
JP2005075826A (ja) 2003-08-29 2005-03-24 Boehringer Ingelheim Internatl Gmbh 多孔質シリカ担体を含有する徐放性製剤
JP2005091988A (ja) 2003-09-19 2005-04-07 Konica Minolta Medical & Graphic Inc 熱現像感光材料及び画像形成方法
EP1675576A1 (en) 2003-10-03 2006-07-05 LifeCycle Pharma A/S A method for preparing modified release pharmaceutical compositions
US20050096390A1 (en) 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US20050095287A1 (en) 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
US7834043B2 (en) 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
EP1729766A1 (en) 2004-03-01 2006-12-13 LEK Pharmaceuticals D.D. Pharmaceutical formulation
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
WO2005105040A2 (en) 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP3287130A1 (en) 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors
JP2006003701A (ja) 2004-06-18 2006-01-05 Konica Minolta Medical & Graphic Inc 熱現像感光材料および画像形成方法
CN101001613B (zh) 2004-06-28 2010-09-29 生命周期药物公司 作为液体制剂载体的多孔片剂
WO2006014282A2 (en) * 2004-07-06 2006-02-09 Abbott Laboratories Prodrugs of hiv protease inhibitors
AR045841A1 (es) 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
EP2266579A1 (en) 2004-10-19 2010-12-29 Achillion Pharmaceuticals, Inc. Pharmaceutical composition comprising elvucitavine
US7786153B2 (en) * 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US20070014854A1 (en) 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
EA018544B1 (ru) 2005-12-30 2013-08-30 Джилид Сайэнс, Инк. Способ лечения ретровирусной инфекции
US20090233964A1 (en) 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP1973529B1 (en) 2006-01-05 2011-05-25 LifeCycle Pharma A/S Disintegrating loadable tablets
EP1990062A1 (en) 2006-02-20 2008-11-12 ASAHI BREWERIES, Ltd. Granules, tablets and method of producing the same
EP1998759A2 (en) 2006-03-23 2008-12-10 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
EA020489B1 (ru) 2006-07-07 2014-11-28 Джилид Сайэнс, Инк. Модуляторы фармакокинетических свойств лекарственных средств
AU2007283196A1 (en) 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition
WO2008027932A2 (en) 2006-08-31 2008-03-06 Abbott Laboratories Cytochrome p450 oxidase inhibitors and uses thereof
EP2063862A2 (en) 2006-09-04 2009-06-03 Matrix Laboratories Ltd Pharmaceutical formulation for use in hiv therapy
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
CN101679325B (zh) 2007-02-23 2013-08-28 吉里德科学公司 治疗剂的药代动力学特性调节剂
JP5547067B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療組成物およびその使用
US20090093467A1 (en) * 2007-06-29 2009-04-09 Gilead Sciences, Inc. Therapeutic compositions and methods
KR20100040896A (ko) 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
US8557534B2 (en) 2007-12-27 2013-10-15 Baxter International Inc. Method and compositions for specifically detecting physiologically acceptable polymer molecules
CN103479584A (zh) * 2008-05-02 2014-01-01 吉里德科学公司 固体载体颗粒在改善药物制剂加工性中的应用
CN102307573B (zh) * 2009-02-06 2013-09-11 吉里德科学公司 用于联合治疗的片剂
EP2238979A1 (en) 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
CN104040747B (zh) 2012-01-10 2016-08-24 捷恩智株式会社 发光层用材料、使用其的有机电场发光元件、显示装置及照明装置
WO2013116730A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

Also Published As

Publication number Publication date
NZ579802A (en) 2012-04-27
NO2017002I1 (no) 2017-01-12
PT2487162T (pt) 2016-11-23
CY1118227T1 (el) 2017-06-28
HRP20161428T1 (hr) 2016-12-16
PL3150586T3 (pl) 2020-06-01
AU2008218186C1 (en) 2014-07-17
EP2487161A1 (en) 2012-08-15
HUE031707T2 (en) 2017-07-28
CA2678907C (en) 2014-06-17
LT3150586T (lt) 2020-03-10
HK1137451A1 (en) 2010-07-30
AP2013007042A0 (en) 2013-08-31
PT2487163T (pt) 2016-11-21
FR17C1000I2 (fr) 2019-03-22
CY1122761T1 (el) 2020-11-25
FR17C1001I1 (fr) 2017-03-17
EP2487161B2 (en) 2024-06-05
NO2017001I1 (no) 2017-01-12
LT2487162T (lt) 2016-11-10
PT2487161T (pt) 2016-11-10
IL200550A0 (en) 2010-05-17
HRP20161502T1 (hr) 2016-12-16
JP2014088441A (ja) 2014-05-15
JP2017171695A (ja) 2017-09-28
ES2602784T3 (es) 2017-02-22
CY2017001PI2 (el) 2017-09-13
EP3150586A1 (en) 2017-04-05
ZA200905882B (en) 2018-12-19
JP2011231132A (ja) 2011-11-17
FR20C1021I1 (fr) 2020-07-31
FR17C1002I1 (fr) 2017-03-17
CY2020011I2 (el) 2020-11-25
LTPA2016039I1 (lt) 2017-01-10
PL2487162T3 (pl) 2017-03-31
EP4403221A2 (en) 2024-07-24
FR17C1001I2 (fr) 2019-05-17
LT2487161T (lt) 2016-11-10
CY2017003I1 (el) 2017-06-28
AR065439A1 (es) 2009-06-10
ES2601820T3 (es) 2017-02-16
LTPA2020508I1 (lt) 2020-06-25
US8486942B2 (en) 2013-07-16
ES2525454T3 (es) 2014-12-23
HRP20200349T1 (hr) 2020-06-12
DK3150586T3 (da) 2020-02-17
EP2118082B1 (en) 2014-10-01
JP4881446B2 (ja) 2012-02-22
CN101679325B (zh) 2013-08-28
LTPA2016040I1 (lt) 2017-01-10
CN103435570B (zh) 2015-06-10
CY2020011I1 (el) 2020-11-25
HRP20161476T4 (hr) 2024-07-05
LTC2487162I2 (lt) 2022-06-27
HUE029843T2 (en) 2017-04-28
US9891239B2 (en) 2018-02-13
LT2487163T (lt) 2016-10-25
ES2603617T3 (es) 2017-02-28
ES2601820T5 (es) 2024-10-31
JP2016121193A (ja) 2016-07-07
HUE029842T2 (en) 2017-04-28
KR101577698B1 (ko) 2015-12-15
WO2008103949A1 (en) 2008-08-28
KR101664154B1 (ko) 2016-10-10
EP3150586B1 (en) 2020-01-08
PT3150586T (pt) 2020-03-31
CY1118292T1 (el) 2017-06-28
SI3150586T1 (sl) 2020-03-31
EA200901155A1 (ru) 2010-02-26
MX2009008935A (es) 2009-11-02
LUC00156I1 (el) 2020-06-02
PT2487166T (pt) 2016-10-17
NO2017002I2 (no) 2017-01-12
LTC2487166I2 (lt) 2021-10-11
FR17C1002I2 (fr) 2019-03-22
BRPI0807581A2 (pt) 2014-07-01
CY2017001PI1 (el) 2017-09-13
PL2487161T5 (pl) 2024-09-09
JP2015078241A (ja) 2015-04-23
JP2019059790A (ja) 2019-04-18
PT2118082E (pt) 2014-12-12
TW200904419A (en) 2009-02-01
CY2017002I1 (el) 2017-06-28
HRP20161476T1 (hr) 2016-12-16
US20160069915A1 (en) 2016-03-10
CY2017003I2 (el) 2017-06-28
HUS1600054I1 (hu) 2017-01-30
JP2016172773A (ja) 2016-09-29
AP3915A (en) 2016-11-29
HUE029866T2 (en) 2017-03-28
US20100189687A1 (en) 2010-07-29
FR17C1000I1 (fr) 2017-03-17
LTPA2016038I1 (lt) 2017-01-10
AP2986A (en) 2014-09-30
CN103435570A (zh) 2013-12-11
EP2118082A1 (en) 2009-11-18
AP2009004964A0 (en) 2009-10-31
JP6147282B2 (ja) 2017-06-14
TWI533868B (zh) 2016-05-21
HUS2000013I1 (hu) 2020-06-29
JP5554300B2 (ja) 2014-07-23
EP4403221A3 (en) 2024-10-09
JP6192776B2 (ja) 2017-09-06
CN101679325A (zh) 2010-03-24
US20150139948A1 (en) 2015-05-21
SG183059A1 (en) 2012-08-30
EP2487161B1 (en) 2016-08-10
LUC00156I2 (el) 2021-02-17
LTC3150586I2 (lt) 2022-05-10
JP2021001236A (ja) 2021-01-07
ES2603645T3 (es) 2017-02-28
CY2017002I2 (el) 2017-06-28
US20140017199A1 (en) 2014-01-16
ES2779826T3 (es) 2020-08-20
DK2487166T3 (en) 2017-02-20
AU2008218186B2 (en) 2014-01-23
JP2010519314A (ja) 2010-06-03
US20170158647A1 (en) 2017-06-08
KR20090122261A (ko) 2009-11-26
HRP20161371T1 (hr) 2016-12-02
LT2487166T (lt) 2016-11-10
EA019893B1 (ru) 2014-07-30
CY1118219T1 (el) 2017-06-28
NO2020011I1 (no) 2020-06-05
FI2487161T4 (fi) 2024-06-06
US8148374B2 (en) 2012-04-03
US20080207620A1 (en) 2008-08-28
EP3689353A1 (en) 2020-08-05
CA2678907A1 (en) 2008-08-28
PL2487161T3 (pl) 2017-03-31
SG10201705929QA (en) 2017-08-30
LTC2487163I2 (lt) 2022-06-27
JP6147388B2 (ja) 2017-06-14
AU2008218186A1 (en) 2008-08-28
US20120237478A1 (en) 2012-09-20
KR20150056665A (ko) 2015-05-26
NO2017003I1 (no) 2017-01-12

Similar Documents

Publication Publication Date Title
CY1122761T1 (el) Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
CY1121729T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων
CY1119176T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
CY1113352T1 (el) Ενωση σπειρο-δακτυλιου και χρηση αυτης για ιατρικους σκοπους
CY1118128T1 (el) Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
CY1114608T1 (el) Θεραπειες συνδυασμου που περιλαμβανουν κινοξαλινη αναστολεα pι3k αλφα για χρηση στην θεραπεια του καρκινου
CY1117424T1 (el) Βενζοδιαζεπινικος αναστολεας bromodomain
CY1119547T1 (el) Ενωσεις, συνθεσεις και μεθοδοι χρησιμες για κινητοποιηση χοληστερολης
EP2613782A4 (en) INDAZONE DERIVATIVES AS ERK HEMMER
EA201000886A1 (ru) Органические соединения
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
CO6531452A2 (es) Piperidinas sustituidas que aumentan la actividad de p53 y sus usos
CY1114521T1 (el) Ενωσεις βενζαμιδιου χρησιμες ως αναστολεις αποακετυλασων ιστονων
CY1112499T1 (el) Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
CY1116645T1 (el) Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
CY1108729T1 (el) 3,11b-cis-διυδpotetpabenazinh για την θεραπευτικη αντιμετωπιση μιας πολλαπλασιαστικης νοσου ή φλεγμονωδους παθησης
CY1123576T1 (el) Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib
CY1115013T1 (el) Διαμορφωτες υποδοχεα 7 που προσομοιαζει toll